FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
· · · · · · · · · · · · · · · · · · ·		

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

	OMB APPROVAL								
	OMB Number:	3235-0287							
	Estimated average burde	en							
l	hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Baeuerle Patrick</u>						2. Issuer Name and Ticker or Trading Symbol Cullinan Oncology, Inc. [CGEM]								Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner Officer (check title) Other (cree it)						
(Last) (First) (Middle) C/O CULLINAN ONCOLOGY, INC. ONE MAIN STREET, SUITE 520						3. Date of Earliest Transaction (Month/Day/Year) 09/08/2021								- X Officer (give title Other (specify below) See Remarks						
——————————————————————————————————————							4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street) CAMBRIDGE MA 02142														X Form filed by One Reporting Person Form filed by More than One Reporting Person						
(City)	(S	tate)	(Zip)											1 01301						
		Tab	ole I - No	n-Deri	vativ	e Se	curit	ies Ac	quired	, Di	sposed o	f, or Be	neficia	ly Owned	l					
Date				2. Trans Date (Month/I		Execution Date,			3. Transaction Code (Instr. r) 8)		4. Securities Acquired (A) of Disposed Of (D) (Instr. 3, 4 5)			Beneficially Owned Following		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership		
									Code	v	Amount	(A) or (D)	Price	Reported Transaction (Instr. 3 and				(Instr. 4)		
Common Stock				09/08	08/2021				М		11,000	A	\$4.3	11,0	11,000		D			
Common Stock				09/08	3/2021	/2021					11,000	D	\$28.4	5 0	0		D			
Common Stock													341,434			I	See Footnote ⁽²⁾			
		•	Table II								osed of, convertil			Owned						
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deeme Execution if any (Month/Da	n Date,	4. Transa Code (8)				6. Date Expirati (Month/	on Da		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	ve ies ially ng ed ction(s)	10. Ownersh Form: Direct (D or Indirec (I) (Instr.	Beneficia Ownersh tt (Instr. 4)		
					Code	v	(A)	(D)	Date Exercisa	able	Expiration Date	Title	Amount or Number of Shares							
Stock Option (Right to Buy)	\$4.3	09/08/2021			M			11,000	(3)		10/28/2030	Common Stock	11,000	\$0.00	240,	114	D			

Explanation of Responses:

- 1. Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on April 30, 2021.
- 2. Shares held directly by APAK Solutions GmbH. The Reporting Person is managing director of APAK Solutions GmbH. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein.
- 3. 25% of the shares vested on September 1, 2019, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.

Remarks:

Acting Chief Scientific Officer, Biologics

/s/ Jeffrey Trigilio, Attorney-in-Fact 09/09/2021

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.